Disc MedicineIRON
IRON
About: Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
Employees: 78
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
107% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 28
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
9% more funds holding
Funds holding: 121 [Q2] → 132 (+11) [Q3]
4% more capital invested
Capital invested by funds: $1.3B [Q2] → $1.35B (+$54.8M) [Q3]
4.55% less ownership
Funds ownership: 96.9% [Q2] → 92.35% (-4.55%) [Q3]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 7 (-1) [Q3]
51% less call options, than puts
Call options by funds: $437K | Put options by funds: $884K
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
8%
upside
Avg. target
$90
39%
upside
High target
$118
82%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Stifel Benjamin Burnett 36% 1-year accuracy 5 / 14 met price target | 38%upside $90 | Buy Maintained | 10 Dec 2024 |
HC Wainwright & Co. Douglas Tsao 41% 1-year accuracy 68 / 167 met price target | 82%upside $118 | Buy Reiterated | 9 Dec 2024 |
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target | 8%upside $70 | Sector Outperform Maintained | 5 Nov 2024 |
Jefferies Roger Song 19% 1-year accuracy 3 / 16 met price target | 37%upside $89 | Buy Initiated | 23 Oct 2024 |
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target | 31%upside $85 | Overweight Reiterated | 15 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Diego, CA. This year's presentations included updates from the BEACON and AURORA trials of bitopertin in patients with erythropoietic protoporphyria (EPP) and the Phase 1 SAD/MAD trial of DISC-3405 in healthy volunteers. Additionally, Disc presented a real-world patient survey highlighting the disease burden of EPP and multiple preclinical models highlighting the potential benefits of bitopertin, DISC-0974, and DISC-3405 in existing and new indications. The collection of data supports Disc's continued advancement of all three clinical candidates and provides evidence for expansion opportunities in new indications.
Neutral
GlobeNewsWire
2 weeks ago
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive updated results from a Phase 1b trial of DISC-0974 in patients with myelofibrosis (MF) and anemia. The data, presented in an oral session at the 2024 American Society of Hematology (ASH) annual meeting in San Diego, CA, demonstrated that treatment with DISC-0974 results in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types.
Neutral
GlobeNewsWire
1 month ago
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences:
Neutral
GlobeNewsWire
1 month ago
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. This financing provides funding options to support anticipated key catalysts, including the expected initiation of a confirmatory study of bitopertin in erythropoietic protoporphyria (EPP), a Phase 2 study of DISC-0974 in anemia of myelofibrosis (MF) and a multiple dose study in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD), and a Phase 2 study of DISC-3405 in polycythemia vera (PV).
Neutral
GlobeNewsWire
1 month ago
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), supporting the regulatory path forward for bitopertin in EPP.
Neutral
GlobeNewsWire
1 month ago
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST.
Neutral
GlobeNewsWire
2 months ago
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia, including results from the 40 mg and 60 mg single ascending dose (SAD) cohorts. The data presented at the 2024 American Society of Nephrology (ASN) Kidney Week in San Diego, CA demonstrated that a single dose of DISC-0974 results in sustained suppression of hepcidin and mobilization of iron, and increased erythropoiesis and levels of hemoglobin in NDD-CKD patients with anemia.
Neutral
GlobeNewsWire
2 months ago
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced upcoming clinical data to be presented at the 2024 American Society of Nephrology (ASN) Kidney Week, which will be held in San Diego, CA on October 24-27, 2024. The poster will report on additional SAD cohorts from the Phase 1b, randomized, placebo-controlled study of DISC-0974 in patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia. This study was designed to assess safety as well as changes to hepcidin, iron, and key hematologic parameters.
Neutral
GlobeNewsWire
3 months ago
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs
Neutral
GlobeNewsWire
3 months ago
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:
Charts implemented using Lightweight Charts™